You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Oncology
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
Login
Username:

Password:


Related Headlines

Diakonos Oncology's DOC1021 granted US FDA Fast Track Designation for unresectable or metastatic cutaneous melanoma

Racura Oncology identifies mechanism of action for (E,E)-bisantrene

ZYUS Life Sciences receives second US pain management patent

Citius Oncology to accelerate LYMPHIR commercialisation with up to USD36.5m in debt and equity capital

Photocure study supports cost-effectiveness of blue light cystoscopy

Telix Pharmaceuticals' MAA for TLX101-Px (Pixlumi) accepted for European review

FDB introduces gravimetric content to improve IV medication compounding

Curocell secures full approval for RIMQARTO to enter CAR-T therapy market

European Commission clears first pertuzumab biosimilar in Europe

C-Ray Therapeutics' Copper-64 (Cu-64) Type II DMF gains FDA acceptance

GSK hepatitis B therapy bepirovirsen gains FDA priority review and breakthrough designation

Xcovery and EVERSANA partner for US commmercialisation of lung cancer drug Ensacove

Jazz Pharmaceuticals reports FDA acceptance and Priority Review of sBLA for Ziihera (zanidatamab-hrii) combinations in first-line HER2+ locally advanced or metastatic GEA

Cantargia reports early remission data from nadunolimab trial in MDS and AML

WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026